243 related articles for article (PubMed ID: 10076002)
1. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes.
Medina MF; Joshi S
Nucleic Acids Res; 1999 Apr; 27(7):1698-708. PubMed ID: 10076002
[TBL] [Abstract][Full Text] [Related]
2. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
Sun LQ; Wang L; Gerlach WL; Symonds G
Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
[TBL] [Abstract][Full Text] [Related]
3. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
Zhou C; Bahner I; Rossi JJ; Kohn DB
Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
[TBL] [Abstract][Full Text] [Related]
4. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
[TBL] [Abstract][Full Text] [Related]
5. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
Tabler M; Homann M; Tzortzakaki S; Sczakiel G
Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
Ramezani A; Ding SF; Joshi S
Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
[TBL] [Abstract][Full Text] [Related]
8. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1.
Ramezani A; Ma XZ; Nazari R; Joshi S
Front Biosci; 2002 Feb; 7():a29-36. PubMed ID: 11815297
[TBL] [Abstract][Full Text] [Related]
9. Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry.
Zhang X; Iwatani Y; Shimayama T; Yamada R; Koito A; Xu Y; Sakai H; Uchiyama T; Hattori T
Antisense Nucleic Acid Drug Dev; 1998 Dec; 8(6):441-50. PubMed ID: 9918108
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.
Ramezani A; Joshi S
Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
[TBL] [Abstract][Full Text] [Related]
12. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
[TBL] [Abstract][Full Text] [Related]
13. A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly.
Westaway SK; Larson GP; Li S; Zaia JA; Rossi JJ
Nucleic Acids Symp Ser; 1995; (33):194-9. PubMed ID: 8643367
[TBL] [Abstract][Full Text] [Related]
14. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
[TBL] [Abstract][Full Text] [Related]
15. Attempts to obtain more efficient GAC-cleaving hammerhead ribozymes by in vitro selection.
Kore AR; Carola C; Eckstein F
Bioorg Med Chem; 2000 Jul; 8(7):1767-71. PubMed ID: 10976525
[TBL] [Abstract][Full Text] [Related]
16. Length variation of helix III in a hammerhead ribozyme and its influence on cleavage activity.
Hammann C; Martinez E; Moosbauer J; Hormes R; Tabler M
Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):25-31. PubMed ID: 10192286
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of viral multiplication by hammerhead ribozymes targeted against the polymerase gene of mouse hepatitis virus.
Maeda A; Mizutani T; Hayashi M; Watanabe T; Namioka S
J Vet Med Sci; 1994 Oct; 56(5):939-45. PubMed ID: 7532438
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity of RNA molecules containing self-releasing ribozymes targeted to lymphocytic choriomeningitis virus.
Xing Z; Mahadeviah S; Whitton JL
Antisense Res Dev; 1995; 5(3):203-12. PubMed ID: 8785476
[TBL] [Abstract][Full Text] [Related]
19. Virion encapsidation of tRNA(3Lys)-ribozyme chimeric RNAs inhibits HIV infection.
Westaway SK; Cagnon L; Chang Z; Li S; Li H; Larson GP; Zaia JA; Rossi JJ
Antisense Nucleic Acid Drug Dev; 1998 Jun; 8(3):185-97. PubMed ID: 9669656
[TBL] [Abstract][Full Text] [Related]
20. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines.
Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G
Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
